128 related articles for article (PubMed ID: 23182551)
1. From genes to metabolomics in renal cell carcinoma translational research.
Mulders PF
Eur Urol; 2013 Feb; 63(2):252-3. PubMed ID: 23182551
[No Abstract] [Full Text] [Related]
2. miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2α regulation.
Moch H; Lukamowicz-Rajska M
Cancer Discov; 2014 Jan; 4(1):22-4. PubMed ID: 24402943
[TBL] [Abstract][Full Text] [Related]
3. Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2α Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma.
Callahan CL; Moore L; Lenz P; Linehan WM; Nickerson ML; Rothman N; Purdue MP
Eur Urol; 2019 May; 75(5):882-884. PubMed ID: 30655088
[No Abstract] [Full Text] [Related]
4. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.
Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S
Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126
[TBL] [Abstract][Full Text] [Related]
5. The Tale of Two Hypoxia-Inducible Factors in Renal Cell Carcinoma.
Nanus DM; Gudas LJ
Eur Urol; 2016 Apr; 69(4):658-659. PubMed ID: 26431912
[No Abstract] [Full Text] [Related]
6. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
8. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of kidney cancer: from the lab to clinical practice.
Sudarshan S; Karam JA; Brugarolas J; Thompson RH; Uzzo R; Rini B; Margulis V; Patard JJ; Escudier B; Linehan WM
Eur Urol; 2013 Feb; 63(2):244-51. PubMed ID: 23063455
[TBL] [Abstract][Full Text] [Related]
10. Two HIFs may be better than one.
Seagroves T; Johnson RS
Cancer Cell; 2002 Apr; 1(3):211-3. PubMed ID: 12086854
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel interferon-α2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro.
Fukui N; Kageyama Y; Higashi Y; Kihara K; Kizaka-Kondoh S; Hiraoka M; Shinojima T; Suzuki K; Oya M
Int J Clin Oncol; 2014; 19(3):497-504. PubMed ID: 23739923
[TBL] [Abstract][Full Text] [Related]
12. Vhl deletion in renal epithelia causes HIF-1α-dependent, HIF-2α-independent angiogenesis and constitutive diuresis.
Schönenberger D; Rajski M; Harlander S; Frew IJ
Oncotarget; 2016 Sep; 7(38):60971-60985. PubMed ID: 27528422
[TBL] [Abstract][Full Text] [Related]
13. Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma.
Liu W; Chen H; Wong N; Haynes W; Baker CM; Wang X
Cancer Lett; 2017 May; 394():65-75. PubMed ID: 28257806
[TBL] [Abstract][Full Text] [Related]
14. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
15. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
16. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
17. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
18. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
19. Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist.
Ferguson JE; Matin SF
Eur Urol; 2017 Jun; 71(6):987. PubMed ID: 28237787
[No Abstract] [Full Text] [Related]
20. Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist.
Shenoy N; Pagliaro L
Eur Urol; 2018 Feb; 73(2):304-305. PubMed ID: 29102314
[No Abstract] [Full Text] [Related]
[Next] [New Search]
